Seres Therapeutics Inc (MCRB) concluded trading on Wednesday at a closing price of $0.91, with 11.37 million shares of worth about $10.35 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -25.89% during that period and on January 22, 2025 the price saw a gain of about 24.69%. Currently the company’s common shares owned by public are about 170.20M shares, out of which, 124.81M shares are available for trading.
Stock saw a price change of 18.95% in past 5 days and over the past one month there was a price change of 5.99%. Year-to-date (YTD), MCRB shares are showing a performance of 9.69% which decreased to -25.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.54 but also hit the highest price of $1.53 during that period. The average intraday trading volume for Seres Therapeutics Inc shares is 2.68 million. The stock is currently trading 6.94% above its 20-day simple moving average (SMA20), while that difference is up 11.04% for SMA50 and it goes to 2.89% higher than SMA200.
Seres Therapeutics Inc (NASDAQ: MCRB) currently have 170.20M outstanding shares and institutions hold larger chunk of about 23.57% of that.
The stock has a current market capitalization of $155.63M and its 3Y-monthly beta is at 2.08. It has posted earnings per share of -$1.19 in the same period. It has Quick Ratio of 1.12 while making debt-to-equity ratio of 3.91. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MCRB, volatility over the week remained 12.46% while standing at 8.55% over the month.
Stock’s fiscal year EPS is expected to rise by 86.52% while it is estimated to decrease by -175.37% in next year.
Coverage by Oppenheimer stated Seres Therapeutics Inc (MCRB) stock as an Outperform in their note to investors on June 26, 2023, suggesting a price target of $12 for the stock. On April 21, 2023, JP Morgan Initiated their recommendations, while on July 23, 2021, Goldman Downgrade their ratings for the stock with a price target of $7. Stock get a Neutral rating from Goldman on May 18, 2021.
